Lornoxicam
Lornoxicam is a non-steroidal anti-inflammatory drug (NSAID) that inhibits COX-1 and COX-2. Lornoxicam exhibits both anti-inflammatory and analgesic activities. In vivo, lornoxicam decreases herpetic stromal keratitis induced by herpes simplex virus HSV-1 by decreasing activation of NF-κB and expression of TNF-α. In other animal models, lornoxicam decreases levels of prostaglandin E2 (PGE2) and attenuates Freund’s adjuvant-induced hyperalgesia. Lornoxicam also exhibits some antioxidative and neuroprotective activities, decreasing caspase 3 activity and malondialdehyde levels and increasing superoxide dismutase (SOD) levels to prevent neuronal apoptosis in animal models of brain injury.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18940848
| Cas No. |
70374-39-9 |
|---|---|
| Purity |
≥98% |
| Formula |
C13H10ClN3O4S2 |
| Formula Wt. |
371.82 |
| IUPAC Name |
6-chloro-4-hydroxy-2-methyl-1,1-dioxo-N-pyridin-2-ylthieno[2,3-e]thiazine-3-carboxamide |
| Melting Point |
239-241C (dec) |
| Appearance |
Light yellow crystalline powder |
Topcu I, Vatansever S, Bayram E, et al. The effects of lornoxicam on neuroprotection following diffuse traumatic brain injury in rats. Turk Neurosurg. 2013;23(6):764-71. PMID: 24310460.
Yin J, Huang Z, Xia Y, et al. Lornoxicam suppresses recurrent herpetic stromal keratitis through down-regulation of nuclear factor-kappaB: an experimental study in mice. Mol Vis. 2009 Jun 14;15:1252-9. PMID: 19547717.
Futaki N, Harada M, Sugimoto M, et al. The importance of brain PGE2 inhibition versus paw PGE2 inhibition as a mechanism for the separation of analgesic and antipyretic effects of lornoxicam in rats with paw inflammation. J Pharm Pharmacol. 2009 May;61(5):607-14. PMID: 19405999.
Radhofer-Welte S, Rabasseda X. Lornoxicam, a new potent NSAID with an improved tolerability profile. Drugs Today (Barc). 2000 Jan;36(1):55-76. PMID: 12879104.
